Elite Pharmaceuticals ( (ELTP) ) has issued an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Elite Pharmaceuticals announced the launch of its generic version of Vyvanse® (Lisdexamfetamine Disylate) in various strengths, targeting the ADHD treatment market. The product, which is marketed under the Elite Laboratories, Inc. label, is expected to capture a portion of the $4.3 billion annual sales reported by IQVIA for the original product, potentially enhancing Elite’s market presence in the generic pharmaceutical industry.
More about Elite Pharmaceuticals
Elite Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops, manufactures, and distributes niche generic products. Their product lines include immediate-release and controlled-release solid oral dose products, marketed under the Elite Laboratories label and through third-party licenses. The company operates a cGMP and DEA registered facility for research, development, and manufacturing in Northvale, NJ.
YTD Price Performance: 282.14%
Average Trading Volume: 2,874,817
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $571.6M
Learn more about ELTP stock on TipRanks’ Stock Analysis page.